Skip to main content
. Author manuscript; available in PMC: 2023 Jul 9.
Published in final edited form as: Cancer Discov. 2023 Jan 9;13(1):216–243. doi: 10.1158/2159-8290.CD-22-0561

Figure 6. MCD mutations cause a cumulative expansion of AiBC-like MBCs.

Figure 6.

A-D, FC analysis of (A, C) CD11b+CD11c+ or (B, D) T-BET+ YFP+ MBC.

E, FC analysis of CD11c+ YFP+ MBC.

F, FC analysis of (left) total or (right) T-BET+CD11c+ MBC in non-immunized young animals.

G, FC analysis of Ki67+ AiBC-like MBC in mice from (F). NB illustrate non-proliferating cells.

H, FC analysis of splenic T-BET+CD11c+ MBC in non-immunized mice. Tumor samples are plotted but not considered for statistical analysis.

I, FC analysis of CD138+ cells in animals from (H).

J, BCR mutation burden in splenic B-cells. Values = mean ± SD.

K, Clonality based on productive VDJ combinations. Datasets were down-sampled to a common minimum, to prevent size-based bias.

L, FC analysis of T-BET and CD11b expression in activated B-cells from the spleen or extranodal tumor from an animal in (H).

Values represent mean ± SEM. P-values calculated using unpaired (A-D,F,G-J) or paired (E) two-tailed Student’s t-test with the two-stage step-up method of Benjamini, Krieger and Yekutieli where applicable; or a Kruskal-Wallis test (J,K).